Aura Biosciences, Inc. (AURA)
Largest Insider Buys in Sector
AURA Stock Price History Chart
AURA Stock Performance
About Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Aura Biosciences, Inc.
Over the last 12 months, insiders at Aura Biosciences, Inc. have bought $0 and sold $1.06M worth of Aura Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Aura Biosciences, Inc. have bought $21.79M and sold $473,027 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,560,000 shares for transaction amount of $14.04M was made by Matrix Capital Management Company, LP (10 percent owner) on 2023‑11‑09.
List of Insider Buy and Sell Transactions, Aura Biosciences, Inc.
| 2024-11-18 | Sale | Chief Medical Officer | 11,822 0.0244% | $9.36 | $110,663 | -2.36% | ||
| 2024-10-29 | Sale | See Remarks | 9,200 0.0186% | $10.74 | $98,788 | -16.25% | ||
| 2024-10-29 | Sale | Vice President, Finance | 553 0.0011% | $10.74 | $5,938 | -16.25% | ||
| 2024-10-18 | Sale | See Remarks | 24,992 0.0517% | $12.04 | $300,839 | -23.34% | ||
| 2024-10-18 | Sale | Chief Financial Officer | 25,131 0.0519% | $12.03 | $302,361 | -23.34% | ||
| 2024-10-16 | Sale | Chief Technology Officer | 7,383 0.0163% | $9.85 | $72,723 | -11.90% | ||
| 2024-01-23 | Sale | See Remarks | 15,853 0.0323% | $7.64 | $121,141 | +6.73% | ||
| 2024-01-23 | Sale | Chief Financial Officer | 6,609 0.0135% | $7.64 | $50,521 | +6.73% | ||
| 2023-11-09 | 10 percent owner | 1.56M 5.251% | $9.00 | $14.04M | +14.06% | |||
| 2023-11-08 | director | 19,601 0.0517% | $7.30 | $143,087 | +11.46% | |||
| 2023-11-07 | director | 123,000 0.3185% | $7.17 | $881,910 | +12.73% | |||
| 2023-11-06 | Sale | See Remarks | 7,449 0.0211% | $12.03 | $89,611 | -28.10% | ||
| 2023-11-06 | Sale | Chief Financial Officer | 3,900 0.0111% | $12.07 | $47,054 | -28.10% | ||
| 2023-10-30 | Sale | See Remarks | 9,586 0.0229% | $6.83 | $65,478 | +7.23% | ||
| 2023-10-30 | Sale | Chief Financial Officer | 3,385 0.0081% | $6.82 | $23,091 | +7.23% | ||
| 2023-10-04 | director | 6,566 0.0178% | $8.61 | $56,512 | -7.88% | |||
| 2023-10-03 | director | 13,500 0.0352% | $8.27 | $111,663 | -6.59% | |||
| 2023-01-06 | director | 904 0.0024% | $10.51 | $9,501 | -3.81% | |||
| 2023-01-05 | director | 396 0.001% | $10.00 | $3,960 | -2.60% | |||
| 2022-12-28 | director | 2,000 0.0066% | $9.75 | $19,500 | +3.45% |
Insider Historical Profitability
| Matrix Capital Management Company, LP | 10 percent owner | 6922870 13.8592% | $8.20 | 3 | 0 | <0.0001% |
| Medicxi Ventures Management (Jersey) Ltd | director | 2969352 5.9445% | $8.20 | 1 | 0 | <0.0001% |
| Johnson David Michael | director | 135667 0.2716% | $8.20 | 9 | 0 | <0.0001% |
Institutional Investor Ownership
| Matrix Capital Management Company, L.P. | $54.34M | 13.97 | 6.92M | 0% | +$0 | 0.51 | |
| Eventide Asset Management | $45.55M | 11.71 | 5.8M | 0% | +$0 | 0.74 | |
| Adage Capital Partners Gp L L C | $35.05M | 9.01 | 4.46M | +5.68% | +$1.88M | 0.06 | |
| Citadel Advisors LLC | $28.86M | 7.42 | 3.68M | +1.24% | +$353,077.30 | 0.02 | |
| Medicxi Growth I Lp | $23.86M | 6.14 | 3.04M | 0% | +$0 | 5.31 |